China National Pharmaceutical Group (01177.HK): Bemesumab combined with chemotherapy and sequentially combined with anlotinib has been approved for the first-line treatment of a new indication for squamous non-small cell lung cancer.

Zhuhua Biopharmaceutical (01177.HK) announced that its subsidiary, Chengdu Tianqing Pharmaceutical Group Co., Ltd. (Tianqing), has received approval from the National Medical Products Administration (NMPA) of China for its independently developed Class 1 innovative drug, Bemosuzumab injection (trade name: Andewa), in combination with chemotherapy sequentially along with Anlotinib Hydrochloride capsules (trade name: Fuxingwei), for first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC). This marks the 12th indication for Anlotinib and the 6th indication for Bemosuzumab.